Ablynx Expands Its Anti-Thrombotic Portfolio And Announces Initiation Of A Phase I Study For Alx-0681

GHENT, Belgium, 8 December 2008 - Ablynx [Euronext Brussels: ABLX], a pioneer in the discovery and development of Nanobodies®, a novel class of antibody-derived therapeutic proteins, announced today that it has initiated a double-blind, randomized, placebo-controlled Phase I study in healthy volunteers with ALX-0681. The subjects will receive a subcutaneous injection of the novel anti- thrombotic Nanobody® that selectively targets von Willebrand (vWF) factor.